Research programme: antibody-drug conjugates - Bayer HealthCare

Drug Profile

Research programme: antibody-drug conjugates - Bayer HealthCare

Alternative Names: Anti-C4.4a antibody-drug conjugates; Anti-C4.4a-ADC; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates; Antibody-Eg5 inhibitor conjugates; Antibody-KIF11 inhibitor conjugates; Antibody-kinesin spindle protein inhibitor conjugates; Antibody-KSP inhibitor conjugates; FGFR2-ADC

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Seattle Genetics
  • Class Antibodies; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; KIF11 protein inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical trials in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 02 Sep 2016 The programme is still under preclinical development
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top